Company Profile (AI Text)
Name: Sen-Jam Pharmaceutical
Canonical URL: https://wefunder.com/senjam
Updated at: 2026-06-02T05:00:33Z

Tagline: Transforming Systemic Inflammation
—The Hidden Killer— Into Longer, Healthier Lives
Elevator pitch: We create new drugs to disrupt pain + inflammation that are highly safe and effective while being remarkably accessible and affordable.

Key claims:
- Total raised on Wefunder: 6252498 | citation: https://wefunder.com/senjam#claim-total-raised
- Total investors: 1436 | citation: https://wefunder.com/senjam#claim-total-investors

Verified facts:
- Total raised on Wefunder: 6252498 | observed_at: 2026-06-02T05:00:33Z | expires_at: 2026-06-03T05:00:33Z
- Total investors: 1436 | observed_at: 2026-06-02T05:00:33Z | expires_at: 2026-06-03T05:00:33Z

Computed metrics:
- total_amount_raised: 6252498
- total_investors: 1436
- team_size: 7
- featured_investor_count: 3
- faq_count: 5
- recent_post_count: 10

Quick facts:
- Pioneering immunoregulation to fight inflammaging—hallmark of biological aging | citation: https://wefunder.com/senjam#claim-fact-1
- $730M+ in exits by leadership team Founders and advisors from MIT, Harvard, Mayo, and MSK | citation: https://wefunder.com/senjam#claim-fact-2
- 60+ global patents granted or pending Strong IP protection across 23 countries | citation: https://wefunder.com/senjam#claim-fact-3
- 11-asset pipeline; 4 Phase 2-ready Advancing key programs in URI, metabolic, and pain management | citation: https://wefunder.com/senjam#claim-fact-4
- Partners: NIDA, Duke, KVK-Tech - Trials, studies, and scale manufacturing already underway | citation: https://wefunder.com/senjam#claim-fact-5
- Repurposing FDA-approved drugs = faster clinical path, lower risk, lower development cost | citation: https://wefunder.com/senjam#claim-fact-6
- Featured in Oppenheimer's 2025 Longevity Market Report as a top immunoregulation biotech | citation: https://wefunder.com/senjam#claim-fact-7
- Invest now before Wall Street catches on—Longevity is the next $1T+ wellness market | citation: https://wefunder.com/senjam#claim-fact-8

FAQ:
- Q: Hi, do you all plan on remaining an LLC for tax purposes post note-conversion, and do you anticipate becoming profitable any time soon?
  A: Hi Lucas, We plan on converting to a C-Corp at the end of this year. Our business model is to create value while de-risking during clinical and regulatory development and then license or sell our assets to a commercialization partner. These licenses and/or sales could be very profitable for the company and 1 or 2 could occur within the next 12-18 months. Jim
- Q: Hello, thank you for offering this opportunity. Do you plan to set the company up for an acquisition or have distributions once the company is in a good place financially? I appreciate any context you can provide around the future expectations of the company.
  A: HI David, Our goal is to sell or license all of our assets within 5 years and distribute the proceeds. When an individual asset is sold or licensed, and the proceeds are greater then the operating expenses needed to achieve an appreciable valuation inflection point, we would have a distribution of the excess cash. Our Q4-Executive Summary can be found at the bottom of the campaign page. For reference there are links to market analysis and valuation for 2 of our assets; SJP-001 (Alcohol Hangov...
- Q: will investors get dividends
  A: HI Adrian, Our goal is to sell or license all of our assets within 5 years and distribute the proceeds. When an individual asset is sold or licensed, and the proceeds are greater then the operating expenses needed to achieve an appreciable valuation inflection point, we would have a distribution of the excess cash. Jim
- Q: Hello. It appears to me that your hangover cure is a combination of naproxen, a common over the counter NSAID (e.g. Aleve) and Fexofenadine, a common over the counter antacid (e.g. Allegra). Do you have any propriety IP given that these are readily available to the public?
  A: Hi Cedric, Yes, you can see our entire patent portfolio for our hangover cure in our Q4-Executive Summary at the bottom of the WeFunder campaign page. We have been granted Use & Formulation patents for the US, Japan, Australia, and South Africa. We have just received the Intent to grant for Europe and are still prosecuting in 6 other countries. Jim
- Q: Hi, I really like your target group, but how do you explain the fact that one can buy two separate medications (one NSAID + one antihistamine), readily available, and take them at once? Is it based on the fact that your medication will be branded for these specific cases?
  A: Hi Neofytos, Yes, our product will be branded for its specific use. By obtaining FDA approval, we can make marketing claims, unlike supplements in this category. We will be performing a clinical trial to determine dose optimization of each component within the product. The finished product may not be readily available as individual components. Our product would offer convenience to the consumer, FDA approval, and proper labeling for use. Jim

Recent posts:
- May was a milestone month. Here's where we stand. (2026-05-30T19:08:29Z) https://wefunder.com/feed/329084
- FDA Grants Our End of Phase 2 Meeting Request (2026-05-11T15:09:16Z) https://wefunder.com/feed/319473
- The Real Thing: Delivering On What We Promised (2026-05-05T14:16:56Z) https://wefunder.com/feed/316840
- We Just Asked FDA for the Meeting That Unlocks Phase 3 (2026-04-23T14:10:31Z) https://wefunder.com/feed/306614
- From Hangovers to the Finish Line: A Breakthrough Moment for Sen-Jam (2026-04-17T17:10:31Z) https://wefunder.com/feed/302360
- Patent Granted: Europe Just Said Yes to SJP-002C (2026-04-14T13:43:52Z) https://wefunder.com/feed/299964
- Join us for our Pre-Close Zoom Town Hall at 5pm EST today (2026-04-03T16:20:16Z) https://wefunder.com/feed/294255
- Tonight: The Campaign Closes (2026-04-03T13:29:03Z) https://wefunder.com/feed/294147
- What's happening inside Sen-Jam right now. And the window closes for you tom (2026-04-02T18:34:13Z) https://wefunder.com/feed/293681
- Tomorrow Is the Last Day: Here’s the Full Picture (2026-04-02T13:54:19Z) https://wefunder.com/feed/293448